PubMed · 13252999
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
T KIBEDI, G ZETENY. 1955. [Cardiac calcification].. https://pubmed.ncbi.nlm.nih.gov/13252999/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
Hydroxyapatite has been successfully deposited onto Fecralloy substrate (a metal alloy with 22% Cr, 4.8% Al) by electrophoretic deposition in an attempt to promote the adhesion between coating and substrate, consequently to extend the lifetime of implants. Fecralloy has the ability to generate a dense and stable alpha-Al(2)O(3) layer "in situ" during thermal treatment, which will highly improve the adhesion and the corrosion resistance of the coating system. Phases and morphologies of HA coating were found to vary after sintering according to XRD and SEM analysis. Besides the physicochemical characterization, the effects of the Fecralloy, thermally generated oxide layer, and HA coating on the early and late responses of osteoblasts in vitro were determined. Cellular morphology and proliferation were studied up to 7 days. Quantitative assays of mineralization were conducted up to 14 days. Osteoblasts showed increased cell spreading and cell proliferation on metal substrates, with significantly higher mineralization on HA coating. The results in this study proved that Fecralloy is a biocompatible metal and the HA coating on Fecralloy provides a good candidate for orthopaedic and dental implants.
Sol-gel derived bioactive glasses of the 70S30C (70mol% SiO2, 30mol% CaO) composition have been foamed to produce 3D bioactive scaffolds with hierarchical interconnected pore morphologies similar to trabecular bone. The aim of this study was to investigate primary human osteoblast response to porous bioactive glass scaffolds. The scaffolds supported osteoblast growth and induced differentiation, within the 3-week culture period, as depicted by enhanced ALPase enzymatic activity, without the addition of supplementary factors such as ascorbic acid, beta-glycerophosphate and dexamethasone. This is the first time this has been observed on a bioactive glass that does not contain phosphate. Deposition of extracellular matrix was also confirmed by enhanced production of the extracellular matrix protein collagen type I. SEM showed indications of mineralized bone nodule formation without the addition of growth factors. The 70S30C bioactive glass scaffolds therefore fulfil many of the criteria for an ideal scaffold for bone tissue engineering applications.